Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking The ...

Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of the prior year. It also announced a collaboration with Pfizer.

Highlights,Institutional interest grows as firms like Oppenheimer & Co. Inc. and Atria Investments expand their holdings in ...

Q4 2024 Earnings Call Transcript March 4, 2025 Y-mAbs Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Head-IRMichael Rossi ...

Image source: Getty Images. In January 2025 ... Its pipeline also includes 13 late-stage programs. Summit Therapeutics doesn't have any products on the market yet. However, that status could ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

TherapeuticsMD Inc. closed 71.83% below its 52-week high of $2.61, which the company reached on March 18th.

Following news of an estimates-topping fourth quarter, TG Therapeutics (NASDAQ: TGTX) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market ...

BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...